iTeos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
iTeos Therapeutics, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Pre-acquisition wind-down biotech with failed lead program and uncertain asset value realization. iTeos reported disappointing topline results from the GALAXIES Lung-201 Phase 2 study evaluating belrestotug + dostarlimab combination in first-line PD-L1 high NSCLC. The company is winding down operations and pursuing acquisition by Concentra after failing to advance.
What is iTeos Therapeutics, Inc.'s industry? iTeos Therapeutics, Inc. (iteostherapeutics.com) operates in Biopharmaceutical/Immuno-Oncology. AskCyborg classifies iTeos Therapeutics, Inc. under Biopharmaceutical/Immuno-Oncology in its company registry.
iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for patients with cancer. The company has agreed to be acquired by Concentra Biosciences through a te...
Cyborg Score thesis
Pre-acquisition wind-down biotech with failed lead program and uncertain asset value...
Read the full analyst-debate transcript →Get the Latest iTeos Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeiTeos Therapeutics, Inc. Overview
Pro stress-test →iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for patients with cancer. The company has agreed to be acquired by Concentra Biosciences through a tender offer and merger, followed by delisting from Nasdaq. The company was advancing novel immunotherapy candidates targeting tumor immunosuppression but faced significant clinical setbacks.
Strategic Profile
Pro stress-test →The company's lead candidate belrestotug is a TIGIT antagonist designed to activate immune cells, while its pipeline also includes inupadenant (A2AR antagonist), EOS-984 (ENT1 inhibitor), and EOS-215 (anti-TREM2 antibody). In 2025, iTeos announced a strategic shift, stating its intention to wind down operations and focus on maximizing shareholder value through its cash position and potential asset sales.
Competitive Landscape
Pro stress-test →iTeos competes in the immuno-oncology therapeutic development space with other companies developing checkpoint inhibitors and immune-modulating therapies. Primary competitors include major pharma and clinical-stage biotech firms developing anti-TIGIT, A2AR antagonist, and other immunotherapy approaches for cancer. The competitive landscape features established players from GSK and other major pharma, making it challenging for independent clinical-stage companies.
Industry Context
iTeos Therapeutics, Inc. operates in Biopharmaceutical/Immuno-Oncology.
Key facts
Founded: 2010 · Headquarters: Watertown, Massachusetts, United States · Market cap: ~$389-449 million